SEC Form 4 · accession 0001451612-26-000015

Kymera Therapeutics, Inc. · KYMR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Bruce Booth

Director

Period of report

Jun 23, 2026

Accepted (ET)

Jun 25, 2026 · 9:55 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001815442

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2,F3	Jun 23, 2026	S	1,235	$99.98	D	3,461,521	I	See footnote
Common Stock^F2,F4	Jun 23, 2026	S	173	$99.98	D	613,589	I	See footnote
Common Stock^F5,F3	Jun 24, 2026	S	103,688	$100.42	D	3,357,833	I	See footnote
Common Stock^F5,F4	Jun 24, 2026	S	14,513	$100.42	D	599,076	I	See footnote
Common Stock^F6,F3	Jun 24, 2026	S	14,490	$101.14	D	3,343,343	I	See footnote
Common Stock^F6,F4	Jun 24, 2026	S	2,029	$101.14	D	597,047	I	See footnote
Common Stock^F7,F3	Jun 25, 2026	S	9,994	$107.30	D	3,333,349	I	See footnote
Common Stock^F8,F3	Jun 25, 2026	S	159	$108.02	D	3,333,190	I	See footnote
Common Stock^F9,F3	Jun 25, 2026	S	14,351	$108.83	D	3,318,839	I	See footnote
Common Stock^F10,F3	Jun 25, 2026	S	1,915	$110.30	D	3,316,924	I	See footnote
Common Stock^F11,F3	Jun 25, 2026	S	614	$110.79	D	3,316,310	I	See footnote
Common Stock^F12,F3	Jun 25, 2026	S	719	$111.89	D	3,315,591	I	See footnote
Common Stock^F13,F3	Jun 25, 2026	S	10,215	$113.70	D	3,305,376	I	See footnote
Common Stock^F14,F3	Jun 25, 2026	S	9,229	$114.65	D	3,296,147	I	See footnote
Common Stock^F15,F3	Jun 25, 2026	S	58,205	$115.57	D	3,237,942	I	See footnote
Common Stock^F16,F3	Jun 25, 2026	S	81,500	$116.53	D	3,156,442	I	See footnote
Common Stock^F17,F3	Jun 25, 2026	S	24,268	$117.50	D	3,132,174	I	See footnote
Common Stock^F18,F3	Jun 25, 2026	S	19,089	$118.60	D	3,113,085	I	See footnote
Common Stock^F7,F4	Jun 25, 2026	S	1,399	$107.30	D	595,648	I	See footnote
Common Stock^F8,F4	Jun 25, 2026	S	23	$108.02	D	595,625	I	See footnote
Common Stock^F9,F4	Jun 25, 2026	S	2,011	$108.83	D	593,614	I	See footnote
Common Stock^F10,F4	Jun 25, 2026	S	265	$110.30	D	593,349	I	See footnote
Common Stock^F11,F4	Jun 25, 2026	S	86	$110.79	D	593,263	I	See footnote
Common Stock^F12,F4	Jun 25, 2026	S	100	$111.89	D	593,163	I	See footnote
Common Stock^F13,F4	Jun 25, 2026	S	1,437	$113.70	D	591,726	I	See footnote
Common Stock^F14,F4	Jun 25, 2026	S	1,289	$114.65	D	590,437	I	See footnote
Common Stock^F15,F4	Jun 25, 2026	S	8,389	$115.57	D	582,048	I	See footnote
Common Stock^F16,F4	Jun 25, 2026	S	11,375	$116.53	D	570,673	I	See footnote
Common Stock^F17,F4	Jun 25, 2026	S	3,359	$117.50	D	567,314	I	See footnote
Common Stock^F18,F4	Jun 25, 2026	S	2,646	$118.60	D	564,668	I	See footnote

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.66 to $110.57 inclusive.
F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.72 to $110.96 inclusive.
F12The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.82 to $111.96 inclusive.
F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.0556 to $114.0429 inclusive.
F14The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.0602 to $115.0549 inclusive.
F15The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.0739 to $116.0726 inclusive.
F16The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.0783 to $117.0773 inclusive.
F17The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.0787 to $118.0736 inclusive.
F18The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.0793 to 119.0789 inclusive.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.95 to $100.1037 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5) through (18).
F3These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
F4The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.95 to $100.9487 inclusive.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.95 to $101.5246 inclusive.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.40 to $107.3612 inclusive.
F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.4762 to $108.3781 inclusive.
F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.5492 to $109.4604 inclusive.

Remarks

Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the first of two filings.